摘要
目的探究孟鲁司特钠联合沙美特罗替卡松治疗咳嗽变异性哮喘(CVA)老年患者的临床疗效和不良反应。方法选取2017年1月~2019年2月成都市第三人民医院诊治的CVA老年患者124例,随机数字表法分为对照组和观察组,每组62例。对照组给予沙美特罗替卡松治疗,观察组在对照组基础上加用孟鲁司特钠治疗。比较两组临床疗效和不良反应。结果治疗前两组诱导痰液中白细胞介素17(IL-17)、白细胞介素6(IL-6)和肿瘤坏死因子α(TNF-α)表达差异无统计学意义(P>0.05),治疗后观察组IL-17、IL-6和TNF-α均显著低于对照组(P<0.05)。治疗前两组日间和夜间咳嗽评分差异无统计学意义(P>0.05),治疗后观察组日间和夜间咳嗽评分均显著低于对照组(P<0.05)。观察组临床治疗有效率显著高于对照组(P<0.05)。观察组复发率显著低于对照组(P<0.05)。两组不良反应发生率差异无统计学意义(P>0.05)。结论孟鲁司特钠联合沙美特罗替卡松治疗可以显著降低CVA老年患者肺部IL-17、IL-6和TNF-α表达,减少局部炎症反应,临床疗效显著,使用安全性高。
Objective To detect the effect of montelukast sodium combined with salmeterol and fluticasone in the treatment of older patients with cough variant asthma( CVA). Methods 124 older patients with CVA in the Third People’s Hospital of Chengdu from January 2017 to February 2019 were selected and randomly divided into the control group and the observation group,62 cases in each group. The control group was treated with salmeterol and fluticasone,and the observation group was additionally treated with montelukast sodium on the basis of the control group. The clinical efficacy and adverse reactions were compared between the two groups. Results Before treatment,there were no significant differences in the expression of interleukin-17( IL-17),interleukin-16( IL-6) and tumor necrosis factor-α( TNF-α) in sputum between the two groups( P > 0. 05). After treatment,IL-17,IL-6 and TNF-α expression in the observation group were significantly lower than those in the control group( P < 0. 05). Before treatment,there were no significant differences in the daytime and nighttime cough scores between the two groups( P > 0. 05). After treatment,the daytime and nighttime cough scores in the observation group were significantly lower than those in the control group( P< 0. 05). The response rate in the observation group was higher than that in the control group( P < 0. 05). The recurrent rate in the observation group was lower than that in the control group( P < 0. 05). There were no significant difference in the incidence of adverse reactions between the two groups( P > 0. 05). Conclusion Montelukast sodium combined with salmeterol and fluticasone may decrease the expression of IL-17,IL-6 and TNF-α in the lung,and inhibit inflammatory reaction with safety in older patients with CVA.
作者
苏娴
陈锋
王月宾
胡辉容
严方涛
李国平
Su Xian;Chen Feng;Wang Yuebin;Hu Huirong;Yan Fangtao;Li Guoping(Department of Respiratory Medicine,the Third People's Hospital of Chengdu,Chengdu 610031)
出处
《国际老年医学杂志》
2021年第4期228-230,共3页
International Journal of Geriatrics
基金
国家自然科学基金(81970026)
四川省卫生健康委员会科研课题(重点研究项目)(19ZD002)。
关键词
孟鲁司特钠
沙美特罗替卡松
咳嗽变异性哮喘
炎症反应
老年
Montelukast
Salmeterol and fluticasone
Cough variant asthma
Inflammatory reaction
Older person
作者简介
通讯作者:陈锋,电子邮箱su13880689350@163.com。
